Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;9(2):295-312.
doi: 10.2217/nnm.13.204.

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

Hui Yi Xue  1 , Shimeng Liu, Ho Lun Wong
Affiliations
Review

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

Hui Yi Xue et al. Nanomedicine (Lond). 2014 Feb.

Abstract

siRNAs have immense therapeutic potential for the treatment of various gene-related diseases ranging from cancer, viral infections and neuropathy to autoimmune diseases. However, their bench-to-bedside translation in recent years has faced several challenges, with inefficient siRNA delivery being one of the most frequently encountered issues. In order to improve the siRNA delivery especially for systemic treatment, nanocarriers made of polymers, lipids or inorganic materials have become almost essential. The 'negative' aspects of these carriers such as their nanotoxicity and immunogenicity thus can no longer be overlooked. In this article, we will extensively review the nanotoxicity of siRNA carriers. The strategies for mitigating the risks of nanotoxicity and the methodology for evaluating these strategies will also be discussed. By addressing this often overlooked but important issue, it will help clear the way for siRNAs to fulfill their promise as a versatile class of therapeutic agents.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mello CC, Conte D., Jr Revealing the world of RNA interference. Nature. 2004;431(7006):338–342. - PubMed
    1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. - PubMed
    1. Castel SE, Martienssen RA. RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Gene. 2013;14(2):100–112. - PMC - PubMed
    1. Blake SJ, Bokhari FF, McMillan NA. RNA interference for viral infections. Curr Drug Targets. 2012;13(11):1411–1420. - PubMed
    1. Kumar LD, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. Adv Drug Deliv Rev. 2007;59:87–100. - PubMed

Websites

    1. Nobelprize.org. [Accessed on 1 July 2013];The Nobel Prize in Physiology or Medicine 2006 – Andrew Z Fire, Craig C Mello. www.nobelprize.org/nobel_prizes/medicine/laureates/2006/advanced.html.
    1. ClinicalTrials.gov. [Accessed 1 July 2013];Tolerance and Effect on Intraocular Pressure After Administration of SYL040012. http://clinicaltrials.gov/ct2/show/results/NCT00990743.
    1. ClinicalTrials.gov. [Accessed 1 July 2013];Intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with respiratory syncytial virus. http://clinicaltrials.gov/ct2/show/NCT00496821?term=nct00496821&rank=1.
    1. Tekmira Pharmaceuticals. [Accessed 20 June 2013];Tekmira Pharmaceuticals completes ApoB SNALP Phase 1 clinical trial. (Posted 7 January 2010). http://investor.tekmirapharm.com/releasedetail.cfm?releaseid=534353.
    1. Frederick National Lab – Nanotechnology characterization laboratory. [Accessed 4 July 2013];Assay cascade protocols. http://ncl.cancer.gov/working_assay-cascade.asp. Provides a detailed list of in vitro assays for nanotoxicity evaluation.

Publication types